Claimed Efficacy Benchmarks are not Inherent to Method Using Generic Formulation Richard ChinnFebruary 10, 2020
Patentability for Novelty and Obviousness in an IPR Can be Addressed Without Understanding the Scope of the Claim Richard ChinnFebruary 7, 2020
Prior Art References Combined to Knock Out a Patented Treatment Method, Even as Limited by Pharmacokinetics myersEric MyersDecember 30, 2019
Supreme Court Urged to Reconsider Patent Eligibility Approach—Just Not This Time myersEric MyersDecember 7, 2019
Prosecution History Estoppel Bars Infringement under the Doctrine of Equivalents Eric MyersNovember 27, 2019
Grüneberg and Myers Team Expands with Addition of Experienced Biotech Associate firmEric MyersNovember 12, 2019
Copying is the Sincerest Form of Flattery and Relevant Evidence toward Obviousness Richard ChinnOctober 30, 2019
Cancer Treatment Patent Survives, Even Over Earlier Evidence of Phase II Trials Eric MyersOctober 6, 2019
Dr. Grüneberg to Speak at Practising Law Institute Program on Post-Grant Patent Trials firmEric MyersJuly 8, 2019
